Niraparib Tosylate/Abiraterone Acetate

甲苯磺酸尼拉帕利/醋酸阿比特龙

Report date: 2026/03/26 20:00:17

Base Information

Drug NameNiraparib Tosylate/Abiraterone Acetate
Drug Alias NameAbiraterone acetate/niraparib FoundationOne liquid companion diagnostic尼拉帕利阿比特龙AKEEGA泽倍珂
ClassificationSmall molecules > Steroids
Mechanisms of ActionPoly (ADP-Ribose) polymerase 1 inhibitorsPoly (ADP-Ribose) Polymerase 2 inhibitorsSteroid 17-alpha-hydroxylase inhibitors
TargetsPoly (ADP-Ribose) Polymerase 2Poly (ADP-Ribose) polymerase 1Steroid 17-alpha-hydroxylase
Therapy Area/IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-Resistant
Global Approved IndicationsProstatic Neoplasms, Castration-Resistant
Approved Indications in ChinaProstatic Neoplasms, Castration-Resistant
Original Approved Country/TerritoryEU
Original Approved Date2023/04/19
Country/TerritoryCzechiaBelgiumBulgaria +[33] 
CombinationsYes Niraparib TosylateAbiraterone Acetate
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesJanssen-Cilag International Nv
China Registration ClassN/A

Develop Information

Active CompaniesJohnson & Johnson (China) Investment LtdJanssen-Cilag International NvXian Janssen Pharmaceutical Ltd +[6] 
Inactive CompaniesN/A
Active IndicationsHormone-Sensitive Prostate NeoplasmsProstatic Neoplasms, Castration-Resistant
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A